The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
ArticleNo Access

SPINAL FLUID CHANGES DURING CHLORPROMAZINE THERAPY

Published Online:https://doi.org/10.1176/ajp.115.2.167

Four schizophrenic patients receiving chlorpromazine in doses adequate to produce a Parkinsonian syndrome but with no history or physical findings of other neurological disease showed elevation of cerebrospinal fluid protein ranging from 51 to 108 mg.%.

Further studies are, of course, indicated and are under way. Besides confirming these findings in a larger series and investigating related drugs in the phenothiazine group, it is planned to evaluate the effect of dosage and duration of administration. Thus far the opportunity has been granted to examine spinal fluids before and after chlorpromazine on 3 non-psychiatric patients; all were on lower doses than those ordinarily employed in the treatment of psychosis.

After 30 days of chlorpromazine (average daily dose 400 mg.) during which time none of the patients showed Parkinsonian manifestations, the spinal fluid levels rose in one case from 21 to 47 mg.%, in another from 27 to 55 mg.% and in the third from 45 to 57 mg.%.

It is not now possible to say whether an increase in the cerebrospinal fluid protein content is related to an alteration in barrier permeability, or whether it indicates some degree of breakdown of tissue. The findings are here presented in a preliminary form solely to alert physicians working with this drug to a hitherto undescribed effect. It is hoped that dissemination of this information may prove helpful in evaluating spinal fluid data where certain complications or questions of differential diagnosis may arise in individuals undergoing long-term therapy with this drug.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.